EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority

Hakim-Moulay Dehbi iD, Sean Devlins, Alexia Iasonos iD, Matthew Nankivell, Duncan Gilbert, John O'Quigley

Statistics in Medicine · 2025

DOI: 10.1002/sim.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Hakim-Moulay Dehbi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Clinical Trials Unit, University College London, London, UK. Hauptthemen laut MEDLINE: Antineoplastic Agents, Equivalence Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A dose optimization trial in oncology may be performed to compare an approved dose level of a given drug with a reduced dose level, testing the hypothesis that efficacy is maintained whilst reducing side effects and consequently improving adherence and quality‐of‐life. This is particularly relevant with modern therapeutic agents whose mechanisms of action imply that efficacy may not necessarily be linearly related to the dose. Using a conventional non‐inferiority framework leads to large sample sizes that are often unfeasible in the phase IV setting. An alternative is to use a margin of practical non‐inferiority, which we define in this paper and show how it can be exploited to justify a sample size. Whilst defining the extent of the margin, researchers also pre‐specify the other dimensions of interest, such as receptor occupancy and/or side effects and quality‐of‐life, that will be used to establish practical non‐inferiority if the observed efficacy of the reduced dose level lies within the margin. The comparison of efficacy is based on the observed difference between the reduced and the approved levels, instead of the confidence interval of this difference, leading to a reduction in sample size. The reduction in precision due to the smaller sample size is compensated by formally pre‐specifying the additional dimensions to the decision process, allowing a more thorough assessment of the opportunity to reduce a dose in practice, with the many advantages that this may involve.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsEquivalence Trials as TopicSample SizeHumansDose-Response Relationship, DrugQuality of LifeComputer SimulationModels, StatisticalNeoplasms

Stichwörter der Autor:innen

dosedose optimizationdose reductionrandomized trialsample size calculation

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Comprehensive Clinical Trials Unit, University College London, London, UK.
  • Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
  • MRC Clinical Trials Unit, University College London, London, UK.

ORCID-Profile: Hakim-Moulay Dehbi, Alexia Iasonos

Förderung

  • NCI NIH HHS

Zitieren

APA

Dehbi, H. M., Devlins, S., Iasonos, A., Nankivell, M., Gilbert, D., & O'Quigley, J. (2025). Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority. Statistics in Medicine. https://doi.org/10.1002/sim.70118

Vancouver

Dehbi HM, Devlins S, Iasonos A, Nankivell M, Gilbert D, O'Quigley J. Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority. Statistics in Medicine. 2025. doi:10.1002/sim.70118

BibTeX
@article{Dehbi2025,
  author = {Dehbi, Hakim-Moulay and Devlins, Sean and Iasonos, Alexia and Nankivell, Matthew and Gilbert, Duncan and O'Quigley, John},
  title = {Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70118}
}
Kostenlos starten →